Barclays PLC Acquires 25,106 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Barclays PLC grew its holdings in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 200.5% during the third quarter, Holdings Channel reports. The firm owned 37,625 shares of the company’s stock after purchasing an additional 25,106 shares during the period. Barclays PLC’s holdings in Tyra Biosciences were worth $884,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of TYRA. Janus Henderson Group PLC bought a new position in shares of Tyra Biosciences during the 3rd quarter valued at $24,994,000. Perceptive Advisors LLC grew its stake in Tyra Biosciences by 50.5% in the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after buying an additional 338,208 shares during the last quarter. Ally Bridge Group NY LLC acquired a new position in Tyra Biosciences in the 2nd quarter valued at $4,232,000. Ensign Peak Advisors Inc acquired a new position in Tyra Biosciences in the 2nd quarter valued at $3,047,000. Finally, American Century Companies Inc. grew its stake in Tyra Biosciences by 582.9% in the 2nd quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock valued at $2,723,000 after buying an additional 145,346 shares during the last quarter. Institutional investors own 84.14% of the company’s stock.

Insider Transactions at Tyra Biosciences

In other news, Director Nina S. Kjellson sold 11,078 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $16.17, for a total transaction of $179,131.26. Following the completion of the transaction, the director now directly owns 472,207 shares of the company’s stock, valued at approximately $7,635,587.19. This trade represents a 2.29 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Alan Fuhrman acquired 9,500 shares of Tyra Biosciences stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average cost of $16.00 per share, with a total value of $152,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 12,849 shares in the company, valued at $205,584. This trade represents a 283.67 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders sold 84,160 shares of company stock valued at $1,827,047. Company insiders own 15.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on TYRA shares. Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and raised their target price for the company from $22.00 to $31.00 in a research note on Friday, October 18th. Oppenheimer raised their target price on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research note on Thursday, September 19th. Wedbush reiterated an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a research note on Friday, October 25th. Finally, HC Wainwright decreased their price target on shares of Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tyra Biosciences currently has an average rating of “Buy” and a consensus price target of $31.00.

Tyra Biosciences Price Performance

NASDAQ TYRA opened at $13.90 on Tuesday. The firm has a market capitalization of $703.38 million, a price-to-earnings ratio of -8.63 and a beta of 1.01. The company’s fifty day moving average is $16.56 and its two-hundred day moving average is $19.35. Tyra Biosciences, Inc. has a 52-week low of $11.24 and a 52-week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). As a group, sell-side analysts expect that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.